- Home
- MARPS vs SKYE Comparison
MARPS vs SKYE Comparison
Compare MARPS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | SKYE |
|---|---|---|
| Founded | 1956 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | MARPS | SKYE |
|---|---|---|
| Price | $4.31 | $1.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $68.00 |
| AVG Volume (30 Days) | 4.6K | ★ 43.0K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | ★ 7.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $0.26 |
| 52 Week High | $6.49 | $13.28 |
Technical Indicators
Market Signals| Indicator | MARPS | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 38.80 |
| Support Level | $4.24 | $0.26 |
| Resistance Level | $4.90 | $2.28 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 61.62 | 0.00 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S .-based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of America. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.